- Home
- Search Results
- Page 1 of 1
Search for: All records
-
Total Resources2
- Resource Type
-
0000000002000000
- More
- Availability
-
20
- Author / Contributor
- Filter by Author / Creator
-
-
Patel, Shrina (2)
-
Agili-Shaban, Ruba (1)
-
Ali, Emaan (1)
-
Asaduzzaman, Abu (1)
-
Hasan, Eman (1)
-
Patel, Aayushi (1)
-
Patel, Nandini (1)
-
Potlakayala, Shobha (1)
-
Proano, Renata (1)
-
Riarh, Fatima (1)
-
Rudrabhatla, Sairam (1)
-
#Tyler Phillips, Kenneth E. (0)
-
#Willis, Ciara (0)
-
& Abreu-Ramos, E. D. (0)
-
& Abramson, C. I. (0)
-
& Abreu-Ramos, E. D. (0)
-
& Adams, S.G. (0)
-
& Ahmed, K. (0)
-
& Ahmed, Khadija. (0)
-
& Aina, D.K. Jr. (0)
-
- Filter by Editor
-
-
& Spizer, S. M. (0)
-
& . Spizer, S. (0)
-
& Ahn, J. (0)
-
& Bateiha, S. (0)
-
& Bosch, N. (0)
-
& Brennan K. (0)
-
& Brennan, K. (0)
-
& Chen, B. (0)
-
& Chen, Bodong (0)
-
& Drown, S. (0)
-
& Ferretti, F. (0)
-
& Higgins, A. (0)
-
& J. Peters (0)
-
& Kali, Y. (0)
-
& Ruiz-Arias, P.M. (0)
-
& S. Spitzer (0)
-
& Sahin. I. (0)
-
& Spitzer, S. (0)
-
& Spitzer, S.M. (0)
-
(submitted - in Review for IEEE ICASSP-2024) (0)
-
-
Have feedback or suggestions for a way to improve these results?
!
Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher.
Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?
Some links on this page may take you to non-federal websites. Their policies may differ from this site.
-
Patel, Aayushi; Agili-Shaban, Ruba; Patel, Shrina; Proano, Renata; Riarh, Fatima; Hasan, Eman; Potlakayala, Shobha; Rudrabhatla, Sairam (, . Journal of Pharmacy and Pharmacology Research)Epilepsy is a disease caused by abnormal brain activity due to disturbed nerve cell activity. It is the fourth most common neurological disorder. Only about 7 out of 10 individuals with epilepsy are successfully treated using anti-epileptic drugs. In the pharmaceutical industry, there has been a growing demand for cannabinoids from Cannabis sativa, commonly known as marijuana, for therapeutic, clinical, and nutraceutical supplements. More recently, the legalization of marijuana for clinical research has allowed to further explore the efficacy in the treatment of several neurological disorders like epilepsy. Unlike opioids, cannabinoids are not psychoactive, making it a potentially more favorable therapeutic drug. Most studies showing the efficacy of Cannabis as a treatment strategy point to the pain management associated with the binding of endocannabinoid G coupled protein receptors CB1 and CB2. Though there are cannabinoid therapeutic drugs like Epidiolex approved by the Food and Drug Administration (FDA), plant-based natural compounds are safer, and effective with no side effects.more » « less